News | June 17, 2008

Bracco Breaks the Mold with Cardiac PET Perfusion Imaging

June 18, 2008 – Bracco Diagnostics showcased its Cardiac PET Perfusion Imaging with CardioGen-82, a Rubidium Rb 82 generator and emphasized the advantages of cardiac PET Perfusion Imaging over the current SPECT, at the Society of Nuclear Medicine's 55th Annual Meeting.

The Rb-82/Sr-82 generator, which is FDA cleared, has Sr-82 on the column. When Sr-82 decays, it decays to a new daughter product called Rb-82. The physical half-life for Rb-82 is 75 seconds, which allows for an efficient protocol. By the time the imaging is completed for the rest portion (approximately 6 minutes), stress can follow immediately and then the stress images can be acquired (approximately 6 minutes). The study can be completed in approximately 40-45 minutes.

Key features of Rb-82 are that it has properties similar to Thallium-201 (Tl-201). Rb-82 acts as a potassium analog, allowing for a high extraction fraction at high flow rates. Defects are visualized within 2 – 7 minutes after injection. Due to the short T_ (75 seconds), both sets of images can be acquired using the same sized dose. A new 100 mCi generator arrives every 28 days. Fixed pricing allows many patients to be performed in a day without the hassle of ordering unit doses. All studies are performed under pharmacologic stress (e.g., adenosine, dipyridamole, or dobutamine)

Some of the advantages of cardiac PET Perfusion Imaging over the current SPECT, according to the company are: improved efficiency; lower radiation; exposure; less attenuation artifacts; and improved resolution.

For more information: www.bracco.com

Related Content

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
GU12171120

GU12171120

Sponsored Content | Case Study | Contrast Media Injectors | April 02, 2019
The continuing search for advantages to improve workflow has radiology departments constantly searching for new solut
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...